An Open-Label, Randomized, Multi-Center Study Comparing the Safety and Immunogenicity of HEPLISAV to Engerix-B and Fendrix in Adults on Hemodialysis Who Have Previously Received Hepatitis B Vaccination and Are Not Seroprotected.

Trial Profile

An Open-Label, Randomized, Multi-Center Study Comparing the Safety and Immunogenicity of HEPLISAV to Engerix-B and Fendrix in Adults on Hemodialysis Who Have Previously Received Hepatitis B Vaccination and Are Not Seroprotected.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs V 270 (Primary) ; Hepatitis B vaccine recombinant
  • Indications Hepatitis B
  • Focus Pharmacodynamics; Registrational
  • Sponsors Dynavax Technologies
  • Most Recent Events

    • 12 Jan 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 12 Jan 2011 Actual initiation date (Dec 2010) added as reported by ClinicalTrials.gov.
    • 15 Sep 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top